|
1
|
Lugo-Trampe A, López-Cifuentes D, Mendoza-Pérez P, Tafurt-Cardona Y, Joo-Domínguez ADJ, Rios-Ibarra CP, Espinoza-Ruiz M, Chang-Rueda C, Rodriguez-Sanchez IP, Martinez-Fierro ML, Delgado-Enciso I, Trujillo-Murillo KDC. Nine-Month Trend of IgG Antibody Persistence and Associated Symptoms Post-SARS-CoV-2 Infection. Healthcare (Basel) 2024; 12:948. [PMID: 38727505 PMCID: PMC11083704 DOI: 10.3390/healthcare12090948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2024] [Revised: 04/28/2024] [Accepted: 04/29/2024] [Indexed: 05/13/2024] Open
Abstract
Between 2 and 8.5% of patients who recover from COVID-19 do not develop antibodies, and the durability of IgG antibodies is under scrutiny. Therefore, the presence and persistence of IgM and IgG antibodies were evaluated in a group of patients diagnosed with SARS-CoV-2 from May to August 2020. Out of 2199 suspected COVID-19 cases, 1264 were confirmed for SARS-CoV-2 by rRT-PCR; 328 consented to participate in the study, with 220 participants followed for 9 months, including 124 men (56%) and 96 women (44%). The primary symptoms were headache, dry cough, and fever. IgG antibodies developed in 95% of patients within 4 weeks post-diagnosis, and a second evaluation at 9 months showed that 72.7% still had detectable IgG antibodies. The presence of IgM in one individual (0.45%) suggested the possibility of reinfection.
Collapse
Affiliation(s)
- Angel Lugo-Trampe
- Faculty of Human Medicine, Campus IV, Universidad Autónoma de Chiapas, Tapachula 30700, Mexico
- Genodiagnóstica SA de CV, Tapachula, Chiapas 30700, Mexico
| | - Daniel López-Cifuentes
- Faculty of Chemistry Sciences, Campus IV, Universidad Autónoma de Chiapas, Tapachula 30700, Mexico
| | - Paúl Mendoza-Pérez
- Faculty of Human Medicine, Campus IV, Universidad Autónoma de Chiapas, Tapachula 30700, Mexico
| | - Yaliana Tafurt-Cardona
- Faculty of Human Medicine, Campus IV, Universidad Autónoma de Chiapas, Tapachula 30700, Mexico
| | | | - Clara Patricia Rios-Ibarra
- Medical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco (CIATEJ), Guadalajara 44270, Mexico
| | - Marisol Espinoza-Ruiz
- Faculty of Chemistry Sciences, Campus IV, Universidad Autónoma de Chiapas, Tapachula 30700, Mexico
| | - Consuelo Chang-Rueda
- Faculty of Chemistry Sciences, Campus IV, Universidad Autónoma de Chiapas, Tapachula 30700, Mexico
| | - Iram Pablo Rodriguez-Sanchez
- Molecular and Structural Physiology Laboratory, School of Biological Sciences, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66455, Mexico
| | - Margarita L. Martinez-Fierro
- Molecular Medicine Laboratory, Unidad de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico
| | - Iván Delgado-Enciso
- School of Medicine, University of Colima, Colima 28040, Mexico
- Colima Cancerology State Institute, IMSS-Bienestar, Colima 28085, Mexico
| | | |
Collapse
|
|
2
|
Firinu D, Perra A, Campagna M, Littera R, Meloni F, Sedda F, Conti M, Costanzo G, Erbi M, Usai G, Locci C, Carta MG, Cappai R, Orrù G, Del Giacco S, Coghe F, Chessa L. Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study. Vaccines (Basel) 2021; 9:1478. [PMID: 34960224 DOI: 10.3390/vaccines9121478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
In several countries, thrombotic events after vaccination with ChAdOx1 nCoV-19 have led to heterologous messenger RNA (mRNA) boosting. We tested the antibody response to SARS-CoV-2 spike protein four weeks after heterologous priming with the ChAdOx1 (ChAd) vector vaccine followed by boosting with BNT162b2(ChAd/BNT), comparing data of homologous regimen (BNT/BNT, ChAd/ChAd) subjects positive for SARS-CoV-2 after the first dose of BNT162b2 (BNT1dose/CoV2) and convalescent COVID-19. METHODS healthy subjects naïve for SARS-CoV-2 infection were assessed for serum IgG anti-S-RBD response 21 days after priming (T1), 4 (TFULL) and 15 (T15W) weeks after booster dose. RESULTS The median IgG anti-S-RBD levels at TFULL of Chad/BNT group were significantly higher than the BNT/BNT group and ChAd/ChAd. Those of BNT/BNT group were significantly higher than ChAd/ChAd. IgG anti-S-RBD of BNT1dose/CoV2 group were similar to BNT/BNT, ChAd/BNT and ChAd/Chad group. The levels among COVID-19 convalescents were significantly lower than ChAd/BNT, BNT/BNT, ChAd/Chad and BNT1dose/CoV2. The proportion of subjects reaching an anti-S-RBD titer >75 AU/mL, correlated with high neutralizing titer, was 94% in ChAd/BNT and BNT/BNT, 60% in BNT1dose/CoV2, 25% in ChAd/ChAd and 4.2% in convalescents. At T15W the titer of ChAd/BNT was still significantly higher than other vaccine schedules, while the anti-S-RBD decline was reduced for ChAd/ChAd and similar for other combinations. CONCLUSION Our data highlight the magnitude of IgG anti-S-RBD response in ChAd/BNT dosing, supporting the current national guidelines for heterologous boosting.
Collapse
|
|
3
|
Firinu D, Perra A, Campagna M, Littera R, Meloni F, Sedda F, Conti M, Costanzo G, Erbi M, Usai G, Locci C, Carta MG, Cappai R, Orrù G, Del Giacco S, Coghe F, Chessa L. Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study. Vaccines (Basel) 2021; 9:vaccines9121478. [PMID: 34960224 PMCID: PMC8704060 DOI: 10.3390/vaccines9121478] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 12/08/2021] [Accepted: 12/11/2021] [Indexed: 12/12/2022] Open
Abstract
In several countries, thrombotic events after vaccination with ChAdOx1 nCoV-19 have led to heterologous messenger RNA (mRNA) boosting. We tested the antibody response to SARS-CoV-2 spike protein four weeks after heterologous priming with the ChAdOx1 (ChAd) vector vaccine followed by boosting with BNT162b2(ChAd/BNT), comparing data of homologous regimen (BNT/BNT, ChAd/ChAd) subjects positive for SARS-CoV-2 after the first dose of BNT162b2 (BNT1dose/CoV2) and convalescent COVID-19. Methods: healthy subjects naïve for SARS-CoV-2 infection were assessed for serum IgG anti-S-RBD response 21 days after priming (T1), 4 (TFULL) and 15 (T15W) weeks after booster dose. Results: The median IgG anti-S-RBD levels at TFULL of Chad/BNT group were significantly higher than the BNT/BNT group and ChAd/ChAd. Those of BNT/BNT group were significantly higher than ChAd/ChAd. IgG anti-S-RBD of BNT1dose/CoV2 group were similar to BNT/BNT, ChAd/BNT and ChAd/Chad group. The levels among COVID-19 convalescents were significantly lower than ChAd/BNT, BNT/BNT, ChAd/Chad and BNT1dose/CoV2. The proportion of subjects reaching an anti-S-RBD titer >75 AU/mL, correlated with high neutralizing titer, was 94% in ChAd/BNT and BNT/BNT, 60% in BNT1dose/CoV2, 25% in ChAd/ChAd and 4.2% in convalescents. At T15W the titer of ChAd/BNT was still significantly higher than other vaccine schedules, while the anti-S-RBD decline was reduced for ChAd/ChAd and similar for other combinations. Conclusion: Our data highlight the magnitude of IgG anti-S-RBD response in ChAd/BNT dosing, supporting the current national guidelines for heterologous boosting
Collapse
Affiliation(s)
- Davide Firinu
- Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy; (M.C.); (F.M.); (M.C.); (G.C.); (M.E.); (G.U.); (C.L.); (M.G.C.); (G.O.); (S.D.G.); (L.C.)
- Correspondence: ; Tel.: +39-070-5109-6128; Fax: +39-070-5109-6227
| | - Andrea Perra
- Department of Biomedical Sciences, University of Cagliari, 09100 Cagliari, Italy; (A.P.); (F.S.)
- Associazione per l’Avanzamento della Ricerca per i Trapianti O.d.V., Non Profit Organisation, 09100 Cagliari, Italy;
| | - Marcello Campagna
- Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy; (M.C.); (F.M.); (M.C.); (G.C.); (M.E.); (G.U.); (C.L.); (M.G.C.); (G.O.); (S.D.G.); (L.C.)
| | - Roberto Littera
- Associazione per l’Avanzamento della Ricerca per i Trapianti O.d.V., Non Profit Organisation, 09100 Cagliari, Italy;
- Medical Genetics, Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy
| | - Federico Meloni
- Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy; (M.C.); (F.M.); (M.C.); (G.C.); (M.E.); (G.U.); (C.L.); (M.G.C.); (G.O.); (S.D.G.); (L.C.)
| | - Francesca Sedda
- Department of Biomedical Sciences, University of Cagliari, 09100 Cagliari, Italy; (A.P.); (F.S.)
| | - Maria Conti
- Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy; (M.C.); (F.M.); (M.C.); (G.C.); (M.E.); (G.U.); (C.L.); (M.G.C.); (G.O.); (S.D.G.); (L.C.)
| | - Giulia Costanzo
- Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy; (M.C.); (F.M.); (M.C.); (G.C.); (M.E.); (G.U.); (C.L.); (M.G.C.); (G.O.); (S.D.G.); (L.C.)
| | - Monica Erbi
- Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy; (M.C.); (F.M.); (M.C.); (G.C.); (M.E.); (G.U.); (C.L.); (M.G.C.); (G.O.); (S.D.G.); (L.C.)
| | - Gianmario Usai
- Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy; (M.C.); (F.M.); (M.C.); (G.C.); (M.E.); (G.U.); (C.L.); (M.G.C.); (G.O.); (S.D.G.); (L.C.)
| | - Carlotta Locci
- Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy; (M.C.); (F.M.); (M.C.); (G.C.); (M.E.); (G.U.); (C.L.); (M.G.C.); (G.O.); (S.D.G.); (L.C.)
| | - Mauro Giovanni Carta
- Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy; (M.C.); (F.M.); (M.C.); (G.C.); (M.E.); (G.U.); (C.L.); (M.G.C.); (G.O.); (S.D.G.); (L.C.)
| | - Riccardo Cappai
- Laboratory Clinical Chemical Analysis and Microbiology, University Hospital of Cagliari, 09042 Cagliari, Italy; (R.C.); (F.C.)
| | - Germano Orrù
- Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy; (M.C.); (F.M.); (M.C.); (G.C.); (M.E.); (G.U.); (C.L.); (M.G.C.); (G.O.); (S.D.G.); (L.C.)
| | - Stefano Del Giacco
- Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy; (M.C.); (F.M.); (M.C.); (G.C.); (M.E.); (G.U.); (C.L.); (M.G.C.); (G.O.); (S.D.G.); (L.C.)
| | - Ferdinando Coghe
- Laboratory Clinical Chemical Analysis and Microbiology, University Hospital of Cagliari, 09042 Cagliari, Italy; (R.C.); (F.C.)
| | - Luchino Chessa
- Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy; (M.C.); (F.M.); (M.C.); (G.C.); (M.E.); (G.U.); (C.L.); (M.G.C.); (G.O.); (S.D.G.); (L.C.)
- Associazione per l’Avanzamento della Ricerca per i Trapianti O.d.V., Non Profit Organisation, 09100 Cagliari, Italy;
| |
Collapse
|